Ensysce Biosciences (ENSC) has entered into definitive agreements, providing the Company with an aggregate gross proceeds of approximately $1.1 ...

SAN DIEGO, CA / ACCESS Newswire / March 31, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for ...

Ensysce Biosciences (NASDAQ:ENSC) released its 4Q2024 results that showed a good cash balance of $3.5 million due in large part to the financing activities management has undertaken which we’ve ...

Ensysce Biosciences (NASDAQ:ENSC) is a clinical stage company that is developing treatments designed to have the same pain-relieving capabilities as opioids but come with the ability to inhibit ...

Ensysce Biosciences (ENSC) will host a symposium on Wednesday, September 3, 2025, during PAINWeek 2025, designed to share perspectives with ...

This course is taught together with ENSC 427. Please refer to the ENSC 427 web page for details. Current count of email messages related to ENSC 894 exchanged this term: 124. Course description: This ...

Short interest in Ensysce Biosciences Inc (NASDAQ:ENSC) decreased during the last reporting period, falling from 39.18K to 38.81K. This put 3.1% of the company's publicly available shares short.

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...

There are no SEC filings that match your filter(s), please update your selections to return more records. Nasdaq provides company’s SEC filings, which are financial statements and reports filed ...